Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Urogen's Phase 2 NMIBC Trial Results

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Oct 07, 2021 7:07pm

286 Views

Post# 33986767

RE:RE:RE:Urogen's Phase 2 NMIBC Trial Results

Not the same indication whatsoever and it won't really decrease cases which end up with CIS. UGN-102 may simply replace TURBT procedure which is mainly used for low and intermediate Papillary Bladder cancer, not the high grade CIS which TLT is treating. It will just give a non surgical alternative to TURBT. IMO

Eoganacht wrote: This would be a first line treatment. It could be a replacement for the TURBT surgery that comes before BCG treatment. If successful it might reduce the number of patients that end up BCG-unresponsive. But that's a long way down the road as they don't even have approval for a phase 3 trial yet.

DJDawg wrote:
Not sure I fully understand implications. Competitor for TLT or being used for different set of patients?